Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by juniper88on Apr 08, 2021 8:51pm
152 Views
Post# 32964315

RE:RE:RE:RE:RE:RE:RE:RE:Here is the second part

RE:RE:RE:RE:RE:RE:RE:RE:Here is the second part I am not fed up either. I appreciate his insights. Some things I agree with some I don't. I believe that is normal. But this time I don't see the point of his comment in reply to mine. And by the way, I do not believe TH-1902 is a slam dunk. I believe it has promise, but it is a phase I medicine. There is a very long way to go.
ANALIAS00 wrote: I am not fed up ! You are still providing good information in between your opinion. It is still appreciated by many member of this board.
jfm1330 wrote: You are fed up? I am too, so the right message at the right time. It's true, I am alone in my camp, so I will save my time and yours. I will let you quietly discuss critical questions, like the need for the company to do more self promotion, together, between like-minded people. Result of that will be great. I am sure. We saw where near unanimity led with ibalizumab/Trogarzo. From now on I will keep my supposed knowledge for myself. Bye.


juniper88 wrote: JFM1330, I am not sure why you feel the need to jump on posters all the time with you supposed knowledge.  You come off as very grumpy.  We don't need to be "corrected" by you all the time.  

Obviously, my point was not that those were the only blood test that would be done.  However, those were most likely the blood tests that Dr. Shaw has access to .  Thera, most likely would have access to those test and any blood test that are specifc to the trial, like the Free Docetaxel. 




jfm1330 wrote: This is not a normal chemotherapy session with an approved drug. This is a phase I clinical trial, first human ever injected. They do parmacokinetics tests for all patients, from clinicaltrials.gov: 

The PK profiles of TH1902 and free docetaxel will be evaluated for all patients in Parts 1 and 2.

So it is clear that they follow the fate of the drug in the blood after injection, not just the usual partameters that are tested with an approved and well known drug.



juniper88 wrote: The blood test that the hospital does is fairly standard, usually CBC, Liver function, Electrolytes, LDH, Albumin, and minerals.  Taxol has certain side effects which especially can be observed in the CBC, for example, but not not exclusive to, Neutrophils going down.  To me if the blood work comes out well it is either because the Taxol went where it is supposed to go (i.e., cancer cells) or the Taxol dosage is too low at this point to cause side effects, or a combination of both.

But note too that the patient did not take premeds.  When my wife has received Taxol she had the following premeds: Ondansetron, dexxamethasone, and benadryl.  We were told the first is for vomitting/nausea and the last two for hypersensitivity.  Without these premeds, even at a low dose, a patient can have a reaction.  

To me this at least is encouraging news.


qwerty22 wrote:

Why do you think they are talking about the fate of the drug? Blood works to me is white blood cell counts, liver enzymes etc. It could more be talking about his health rather than the fate of the drug. In fact in my opinion 'the fate of the drug' is a very specialist chromatography or immunological research assay that will not be done in hospital labs and will not be something the doctor can comment on. That sentence is very much said in connection to other statements on the patients reaction to the drug so far.

 

jfm1330 wrote: Thanks, much appreciated. The positive blood test, monitoring of the drug fate, is clearly a good early sign.


 

 

SPCEO1 wrote:

 

 

 

 








<< Previous
Bullboard Posts
Next >>